Detailed Narrative
Strong Q1 FY27 Financial Performance
Yatharth Hospital & Trauma Care Services Limited reported its highest ever quarterly revenue of INR3,927 million in Q1 FY27, marking a robust 51% year-on-year and 15% quarter-on-quarter growth. This strong top-line performance was accompanied by a 39% year-on-year increase in EBITDA. The company's adjusted EBITDA margin, excluding the impact of newer hospitals, stood at 28.1%, reflecting healthy core operations, though the consolidated EBITDA margin was 23.3% due to ramping up new assets.
Success of Acquisition Playbook and New Hospital Ramp-up
The company's acquisition strategy has shown early success, with newer hospitals contributing 27% (INR1,067 million) to the group's revenue. Notably, Faridabad Sector 20 hospital achieved EBITDA breakeven within a record 9 months, significantly ahead of the 12-14 months target, and is now contributing INR12-13 crores in monthly revenue with an ARPOB of INR40,000. The New Delhi hospital has also approached the INR50,000 ARPOB mark, positioning it among premium NCR hospitals, with a monthly revenue run rate of INR8 crores.
Strategic Payer Mix and International Expansion
Yatharth is deliberately focusing on improving its payer mix, with new hospitals operating at 90%+ cash and private insurance patients. This strategy, which sometimes involves restricting government business, aims to enhance ARPOB and profitability. To further this, the company is expanding its global outreach by opening 5 OPD centers and information centers in CIS and African countries, supported by senior marketing personnel, to attract international patients.
Accelerated Capacity Expansion and Future Projects
The company's total bed capacity has expanded to 2,555 beds, and it aims to reach 5,000 beds in approximately 2.5 years, an acceleration from the previously announced 3-year target. The Gurugram hospital construction is progressing as expected, with a go-live target of Q1 next fiscal year and a potential ARPOB of INR50,000+. Brownfield expansions in Noida Extension and Greater Noida are also underway, with capacity expected to come online in 15-18 months.
Impact of Capex on Profitability and Debt Management
PAT was severely impacted by increased depreciation and finance costs, which rose due to significant capital expenditures over the past 12 months. These investments include the acquisition and construction of Gurugram, as well as ordering oncology machines for Faridabad and Model Town. Gross debt increased from INR210 crores in March to INR300 crores, partly due to INR80 crores for acquisition funding. Management expressed comfort with current debt levels, indicating sufficient internal accruals, cash, and debt capacity to fund future capex for the remaining 1,800 beds.
Talent Retention and Shareholder Returns
In recognition of employee efforts, the company approved its first ESOP grant and launched a new ESOP scheme 2026 to attract, retain, and align quality talent. This initiative, alongside fostering a doctor-friendly environment, aims to ensure a stable workforce. For shareholders, the Board approved a maiden interim dividend of 5% of face value, reflecting confidence in the company's growth trajectory and commitment to sharing value created.